Charles River Laboratories International Inc. Sets New 1-Year High at $53.84 (CRL)
Charles River Laboratories International (NYSE:CRL) set a new 52-week high on Friday, Analyst Ratings Network.com reports. The company traded as high as $53.84 and last traded at $53.56, with a volume of 263,623 shares. The stock had previously closed at $52.88.
A number of analysts have recently weighed in on CRL shares. Analysts at Raymond James upgraded shares of Charles River Laboratories International from an “underperform” rating to a “market perform” rating in a research note to investors on Wednesday, December 11th. Separately, analysts at Deutsche Bank initiated coverage on shares of Charles River Laboratories International in a research note to investors on Wednesday, November 20th. They set a “hold” rating and a $55.00 price target on the stock. Finally, analysts at Sterne Agee raised their price target on shares of Charles River Laboratories International from $56.00 to $60.00 in a research note to investors on Friday, November 1st. They now have a “buy” rating on the stock. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $48.27.
In other Charles River Laboratories International news, CFO Thomas Ackerman sold 5,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $52.72, for a total transaction of $263,600.00. Following the transaction, the chief financial officer now directly owns 107,689 shares in the company, valued at approximately $5,677,364. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Charles River Laboratories International has a 52-week low of $38.34 and a 52-week high of $53.81. The stock has a 50-day moving average of $52.3 and a 200-day moving average of $47.62. The company has a market cap of $2.572 billion and a P/E ratio of 25.06.
Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.79 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.70 by $0.09. The company had revenue of $292.10 million for the quarter, compared to the consensus estimate of $290.28 million. During the same quarter in the prior year, the company posted $0.65 earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis.
Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.